They found that UCH-L1 increases in an AD clinical context, alongside other biomarkers, such as Glial Fibrillary Acidic Protein (GFAP) and Tau and Neurofilament Light Chain (NfL), in line with previous reports. Here, MAPT is linked to Alzheimer disease.